One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy is important. We previously reported results after the first year of this randomized trial comparing the use of full-length parathyroid hormone (1–84) alone, alendronate alone, or both combined. In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1–84).

This publication has 16 references indexed in Scilit: